Authors
Sybrand W J Zielhuis, Karen A M de Jong, Hinke Huisman-Siebinga, Lisa T van der Heijden, Bart A W Jacobs, Jos H Beijnen, Hilde Rosing, Chantal F Stockem, Jeroen van Dorp, Michiel S van der Heijden, Alwin D R Huitema
Published in
Clinical and translational science. Volume 19. Issue 11.
Abstract
Patients with locoregionally advanced urothelial cancer (UC) received three pre-operative cycles of ipilimumab and nivolumab in the NABUCCO trial, across three cohorts with different dosing combinations. This study aimed to define the pharmacokinetics (PK) of both drugs in this population and to assess the relationship between the PK and treatment response. Ipilimumab and nivolumab serum concentrations were measured in 139 samples of 52 patients. A population PK model was developed for both drugs using nonlinear mixed-effects modeling. This model was used to examine baseline clearance (CL0)- and exposure-response relationships, with pathological response at surgery as efficacy parameter. A logistic regression model was constructed to quantify these relationships. The developed population PK model adequately described ipilimumab and nivolumab observations. Individual CL0 estimates of both drugs were correlated (correlation coefficient = 0.57). Among patients in the lowest quartile of CL0 of both drugs, twelve out of thirteen patients were responders. In the logistic regression model, a relatively low nivolumab CL0 and high ipilimumab exposure were successfully related to treatment response. The model predicted probability of response was higher for high-dose ipilimumab (3 mg/kg) compared to low-dose ipilimumab (1 mg/kg) (54% vs. 29%, respectively), and was in line with NABUCCO trial outcomes. These results support the hypothesis that for ipilimumab, an exposure-response relationship exists, while this is not the case for nivolumab. Further confirmation of these relationships is warranted, given the limited number of patients included in the analysis.
PMID:
43031519
Bibliographic data and abstract were imported from PubMed on 14 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 8
- Comments 0